Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Neurology Rheumatology Diabetes / Metabolic Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Trial Radar • ClinicalTrials.gov • Registry-linked

Trial Radar

1003 clinical trials with phase, status, specialty and registry links, summarised for rapid clinical review.

1003 recruiting AI clinical summaries
Explore Trial Collections Follow research updates
All Phases Phase I Phase II Phase III Phase IV
Therapeutic Area: All Cardiology / Cardiovascular Dermatology Diabetes / Metabolic Gastroenterology Haematology Infectious Disease Men's Health Mental Health / Psychiatry Nephrology Neurology Oncology Rare Diseases
🔬
Trial Radar

Clinical Trial Intelligence

active not recruiting Phase II Oncology
Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression
FAIM Trial Summary Adding ipatasertib to fulvestrant and palbociclib may improve survival in advanced hormone-receptor positive breast cancer patients without early treatment response.
14 Apr 2026 NCT04920708
active not recruiting Phase II Oncology
A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine
Adults who previously tolerated brigimadlin continue taking tablets every three weeks to assess long-term safety and tumour response.
14 Apr 2026 NCT06619509
● Recruiting Phase II
Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Study
Long-term safety and efficacy study of lunsekimig (a new treatment) in adults with poorly controlled chronic rhinosinusitis with nasal polyps over 52 weeks.
14 Apr 2026 NCT06914908
● Recruiting Phase II Oncology
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
The purpose of this study is to collect long term safety data in subjects who are continuing to derive clinical benefit from treatment with…
14 Apr 2026 NCT02960022
● Recruiting Phase II Oncology
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
The purpose of this study is to assess the anti-tumor activity and safety of amivantamab which will be administered as a co-formulation with recombinant…
14 Apr 2026 NCT05498428
● Recruiting Phase II Oncology
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
The primary purpose of the study is to assess how well amivantamab in combination with lazertinib or in combination with chemotherapy works (antitumor activity)…
14 Apr 2026 NCT06667076
● Recruiting Phase II Oncology
To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer
The purpose of this study is to evaluate the efficacy and safety of inavolisib in combination with fulvestrant compared with inavolisib in combination with…
14 Apr 2026 NCT07368998
● Recruiting Phase II Rheumatology
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn’s Disease
Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. The purpose of this study is to…
14 Apr 2026 NCT06233461
● Recruiting Phase II Oncology
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy…
14 Apr 2026 NCT06667908
● Recruiting Phase II Oncology
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
This study will evaluate the safety and efficacy of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer (PROC) With Cyclin E1 Overexpression.
14 Apr 2026 NCT07023627
● Recruiting Phase II Oncology
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Two drug combinations tested for advanced lung cancer with EGFR mutations: amivantamab plus lazertinib versus amivantamab plus chemotherapy.
13 Apr 2026 NCT06667076
active not recruiting Phase II Cardiology / Cardiovascular
A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis
Trial testing a new drug combination for heart-involved amyloid disease, comparing immediate versus delayed treatment timing.
13 Apr 2026 NCT05250973
● Recruiting Phase II / Phase III
A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).
Aficamten improves symptoms and safety in children with obstructive hypertrophic cardiomyopathy, a serious heart muscle condition.
13 Apr 2026 NCT06412666
● Recruiting Phase II Oncology
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Amivantamab injection tested for safety and effectiveness in advanced cancers, particularly lung cancer with specific genetic mutations.
13 Apr 2026 NCT05498428
active not recruiting Phase II Cardiology / Cardiovascular
A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension
Study testing whether adult-based selexipag doses produce similar blood levels in children aged 2-18 with pulmonary arterial hypertension.
13 Apr 2026 NCT03492177
● Recruiting Phase II
A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease
What is being tested: MZE829, an investigational therapeutic agent, is being evaluated for its safety, tolerability, and ability to reduce albuminuria (protein in urine)…
10 Apr 2026 NCT06830629
● Recruiting Phase II
BAY3401016; Biomarker Study Alport
What is being tested: BAY3401016 is being investigated as a potential therapeutic intervention in Alport syndrome, a rare genetic disorder caused by mutations in…
10 Apr 2026 NCT07211685
● Recruiting Phase II Respiratory / COPD / Asthma
Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma.
Treatment being tested: Lunsekimig (SAR443765), a novel therapeutic agent, is being evaluated for long-term safety and efficacy in adults with asthma through an open-label…
10 Apr 2026 NCT06609239
● Recruiting Phase II Respiratory / COPD / Asthma
A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)
What is being tested: Axatilimab (a CSF1R inhibitor) is being evaluated against best available therapy in paediatric patients with chronic graft-versus-host disease (cGVHD) who…
10 Apr 2026 NCT07124078
● Recruiting Phase II Cardiology / Cardiovascular
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
What is being tested: DM199 (rinvecalinase alfa), a novel therapeutic agent designed to improve outcomes in acute ischemic stroke caused by small and medium…
10 Apr 2026 NCT05065216
● Recruiting Phase II Cardiology / Cardiovascular
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis
What is being tested: CSL300 (clazakizumab), an IL-6 pathway inhibitor, is being evaluated in a two-part trial to identify optimal dosing (phase 2b) and…
10 Apr 2026 NCT05485961
● Recruiting Phase II
BAY3401016; Biomarker Study Alport
BAY3401016 is a new drug that blocks a protein to slow kidney damage progression in adults with rapidly worsening Alport syndrome.
09 Apr 2026 NCT07211685
active not recruiting Phase II Cardiology / Cardiovascular
Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)
Long-term safety and effectiveness study of seralutinib, a new drug treatment, in adults with pulmonary arterial hypertension.
09 Apr 2026 NCT04816604
● Recruiting Phase II / Phase III Neurology
Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
BHV-7000 is being tested to see if it works safely in adults with focal epilepsy that doesn't respond to current drugs.
09 Apr 2026 NCT06309966
● Recruiting Phase II Respiratory / COPD / Asthma
Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma.
Lunsekimig (SAR443765) Long-term Asthma Trial Summary Long-term safety and effectiveness study of lunsekimig injection for adults with asthma over 96 weeks.
09 Apr 2026 NCT06609239
● Recruiting Phase II / Phase III Diabetes / Metabolic
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis
A trial testing clazakizumab (an anti-inflammatory drug) to reduce heart disease and death in dialysis patients with inflammation. Word count: 18 words
09 Apr 2026 NCT05485961
● Recruiting Phase II
Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren’s Disease With Moderate to Severe Systemic Disease Activity
IMVT-1402 tested against placebo in adults with moderate-to-severe primary Sjögren's disease to assess whether it improves symptoms and is safe.
09 Apr 2026 NCT06979531
● Recruiting Phase II
A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia
TransCon CNP (navepegritide) weekly injections versus placebo tested for safety and effectiveness in babies with achondroplasia.
08 Apr 2026 NCT06079398
active not recruiting Phase I / Phase II Oncology
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
GEN1042 antibody tested alone and combined with pembrolizumab, with or without chemotherapy, in patients with solid tumours.
08 Apr 2026 NCT04083599
active not recruiting Phase II Oncology
Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
Gene-edited T-cell therapy trial testing safety and effectiveness in advanced synovial sarcoma and liposarcoma patients.
08 Apr 2026 NCT05993299
● Recruiting Phase II
Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia
Neflamapimod was tested for safety and effectiveness in patients with a progressive language disorder affecting speech fluency.
08 Apr 2026 NCT07033481
active not recruiting Phase II Oncology
Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
Engineered T-cell therapy trial testing safety and effectiveness in advanced synovial sarcoma or liposarcoma patients.
08 Apr 2026 NCT06703346
● Recruiting Phase II Infectious Disease
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa is Recruiting • Phase II • Infectious Disease • NCT07170917. This is a Phase…
08 Apr 2026 NCT07170917
● Recruiting Phase II Diabetes / Metabolic
FrexalimAB in Preservation of Endogenous insULIN Secretion Compared to Placebo in adUlts and Adolescents on Top of inSulin Therapy (FABULINUS)
FrexalimAB in Preservation of Endogenous insULIN Secretion Compared to Placebo in adUlts and Adolescents on Top of inSulin Therapy (FABULINUS) is Recruiting • Phase…
08 Apr 2026 NCT06111586
● Recruiting Phase II
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia is Recruiting • Phase II • NCT05070845. Review the linked registry entry for study…
07 Apr 2026 NCT05070845
● Recruiting Phase II Oncology
A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung…
07 Apr 2026 NCT07063745
● Recruiting Phase II Oncology
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer is Recruiting • Phase II • Oncology •…
07 Apr 2026 NCT07007559
● Recruiting Phase II
Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)
Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW) is Recruiting • Phase II •…
07 Apr 2026 NCT07161037
● Recruiting Phase II Rheumatology
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE) is Recruiting • Phase…
07 Apr 2026 NCT07015983
● Recruiting Phase II Rheumatology
A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis is Recruiting • Phase II • Rheumatology •…
07 Apr 2026 NCT05076175
● Recruiting Phase II Oncology
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01) is Recruiting • Phase…
07 Apr 2026 NCT07100080
● Recruiting Phase II Neurology
A Study of IPN10200 for the Treatment of Cervical Dystonia in Adults
A Study of IPN10200 for the Treatment of Cervical Dystonia in Adults is Recruiting • Phase II • Neurology • NCT06937931. Review the linked…
06 Apr 2026 NCT06937931
● Recruiting Phase II Cardiology / Cardiovascular
Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008) is Recruiting • Phase II • Cardiology / Cardiovascular • NCT05587712.…
06 Apr 2026 NCT05587712
● Recruiting Phase II Respiratory / COPD / Asthma
A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)
A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK) is Recruiting • Phase II • Respiratory / COPD / Asthma…
06 Apr 2026 NCT07116031
● Recruiting Phase II Cardiology / Cardiovascular
Sotagliflozin in Patients With Heart Failure Symptoms and Type 1 Diabetes
Sotagliflozin in Patients With Heart Failure Symptoms and Type 1 Diabetes is Recruiting • Phase II • Cardiology / Cardiovascular • NCT06435156. People with…
06 Apr 2026 NCT06435156
● Recruiting Phase II Oncology
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011) is Recruiting • Phase II • Oncology • NCT06833073.…
06 Apr 2026 NCT06833073
● Recruiting Phase II Oncology
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis is Recruiting • Phase II • Oncology…
06 Apr 2026 NCT04910685
● Recruiting Phase II Oncology
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)…
03 Apr 2026 NCT06534983
● Recruiting Phase II
Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab
Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab is Recruiting…
03 Apr 2026 NCT07039422
active not recruiting Phase I / Phase II Oncology
A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.
A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers. is Active Not…
03 Apr 2026 NCT06116136